

# Zylox-Tonbridge (2190.HK) 2024 Interim Results Presentation

August 2024





This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Zylox-Tonbridge Medical Technology Co., Ltd. (the "Company").

This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and neither this presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Securities may not be offered or sold in the United States absent registration or an available exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act").All the information in this presentation has been provided by the Company and has not been independently verified by its advisers or any of their respective affiliates or associates (collectively, "advisers"). No representation, warranty or undertaking, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries or by its advisers or representatives as to the fairness, accuracy, completeness or correctness of, this presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

This presentation is not intended to provide the basis for evaluating, and should not be considered a recommendation with respect to, any transaction or other matter. Any analyses included herein are not and do not purport to be appraisals of the assets or business of the Company or any of its subsidiaries or affiliates. Nothing in this presentation should be construed as regulatory, valuation, legal, tax, accounting or investment advice. Before you enter into any transaction, you should ensure that you will be responsible for conducting your own due diligence investigation with respect to the Company and fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. Any decision to purchase securities of the Company in any public or private offering should be made solely on the basis of the prospectus and/or international offering circular to be a prepared by the Company in relation to any such contemplated offiguring together with any supplementary pricing information. This presentation or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) (the "Companies Ordinance"), or an advertisement in relation to a prospectus or extract from or ability or ability or a prospectus within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "Securities and Futures Ordinance") or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects", "believes" and "anticipates" and words of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisers or representatives are unaware. These forward looking statements are not a guarantee of future performance. Against the background of these uncertainties, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation is confidential and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time without the prior written consent of the Company or its advisers.

By accepting this presentation, the recipient has agreed, upon request, to return promptly all material received from the Company or its advisers (including this presentation) without retaining any copies. In furnishing this presentation, the Company and its advisers or representatives undertake no obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies therein which may become apparent.


By reading and attending this presentation, you agree to be bound by the foregoing restrictions, and you shall be deemed to have represented to us that you (and any customers you represent) are either (a) a qualified institutional buyer (as defined in Rule 144A under the U.S. Securities Act) or (b) outside the United States (within the meaning of Regulation S under the U.S. Securities Act). You also represent that you (and any customers you represent) are "professional investors" described in Part I of Schedule 1 to the Securities and Futures Ordinance and any subsidiary legislation thereunder (including but not limited to the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong)).

The distribution of this presentation in any jurisdiction may be restricted by law and persons in possession of this presentation should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Any prospective purchaser interested in buying securities of or evaluating the Company is recommended to seek its own independent legal, tax, financial and other professional advice.

# **Business Highlights**





## Sales

Industry leader of promoting innovative ideas and techniques

• The sales network covers more

than 3,000 hospitals, more than 500 secondary distributors

- Ongoing industry benchmarking activities
- VBPs Implementation

## Create new impetus for the growth of our international business

Overseas sales revenue

amounted to 11.49 million RMB,

- 84.2% YOY Growth
- Commercialized in 22
- countries/regions
- Accelerating Overseas Layout

## R&D

- 8 Number of NMPA registration approvals obtained in mid-2024
- The first Flow Diverter with distal closure design in China
- The first self-developed Suture-Mediated Closure system in China
- Proximal beveled port, tapered taper and integrated structure of the Peripheral Venous Stent System
- Other innovative products

**10+** Number of clinical trials conducted simultaneously in the first half of 2024


<sup>5</sup> Number of products in the registration phase



# **Financial Highlights**


• High revenue growth, turn loses into profits






#### **Overseas Sales Rise Sharply in 2022H1-2024H1**

2022H1-2024H1CAGR : **105%** 


















#### Main Source of Revenue 2 COM Drug 腔静脉滤 Snare Retrievable **ZYLOX**\* Coated Retrieval Inferior PTA Balloon **Kit for IVC** Vena Cava Catheter Filter Filter **偃月生辉** 佐诺新 音 **計符** 哭词 2 4131377 ZENFLOW PTA球奏扩张导管 Endovenous ZENFLOW<sup>\*</sup>HP PTAG标项算扩张导管 PTA Balloon 中周球离扩张导 **High Pressure** Radiofrequency Catheter **PTA Balloon** Ablation (RFA) Catheter Catheter M四交克 万能提战 柔顺旸行 耐压可靠 安得制 **Other Launched Products** ZYLOX Unicor ZYLOX®Pho ZENFLEX\* 沿丝人缝 针连壁了 收放有术 4 **Phoenix Peripheral Penguin Peripheral Unicorn Suture-Peripheral Stent** mediated Closure Detachable Fibrous Coil System Venous Stent System (Overseas) System **Embolization System** 为患者 恒创新/Innovation for quality life 7





## 为患者 恒创新/Innovation for quality life 8






Finance income/(costs)-net<sup>1</sup> Other gains/(losses)-net<sup>2</sup>
Other income and expesses

#### Notes:

1. Primarily attributable to a decrease in bank interest income in the Reporting Period 2. Primarily due to net fair value losses from FVPL


#### Unadjusted Net Profit / (Loss )

#### ( in 000' RMB)



Listing expenses	22,733		
Share-based compensation	87,678	85,767	9,306
Adjusted Net Profit / (Loss )	-25,877	7,033	78,171





#### Notes:

1. Total funds at the beginning and end of the period include cash and cash equivalents, term deposits, and financial assets at fair value through profit or loss.

2. We reverse cash flows from financing activities by the amount of principal and interest related to lease payments, and increase the operating cash flows by the same amount. 3. Others referring to exchange gains on cash and cash equivalents.






# Sales and Marketing

• Extensive Sales Network and Rapid Commercialization Progress


Deeply Cultivate the Domestic Market, Continuing to Strengthen the Channel Advantage to Build an Extensive Sales Network





#### **Rapid Commercialization Capabilities**

Numbers of Provincial Procurement Platforms that Newly Launched Products are Included into in Last One Year (Data as of August 9, 2024)



Notes

1. Approval Time: Neurovascular Products: Introducer Sheath 2023.7, Clot Retriever Device II2023.10, Radial Access Distal Support Catheter 2023.11, Embolic Protection System 2024.3, Flow Diverter 2024.3, Intracranial PTA Balloon Catheter II 2024.2, Microcatheter for Intracranial Stent 2023.7 Mechanical Detachable Coil II 2024.1.

为患者 恒创新/Innovation for quality life 12

Peripheral-vascular Products: Peripheral Venous Stent System 2024.1, Peripheral Detachable Embolization Coils 2023.12, Infusion Catheter 2023.9, Tapered PTA Balloon Catheter 2024.1, Second Generation DCB 2024.1, Long Balloon Catheter 2024.3, PTA Scoring Balloon Catheter 2024.3, Suture-mediated Closure System 2024.5.





#### **Doctor training support activities:**

- Covered <u>5</u> stroke centers in Changzhou, Beijing, Zhengzhou, Chenzhou and Kunming, including live surgery broadcast events, devices in vitro demonstration, fun running activities, etc. Accelerates the listing & training of BADDASS and R-DAS training center.
- Relying on a large center of regional influence, the trainees radiate across the country.



#### **Domestic and overseas meetings and panels:**

- Held a total of <u>98</u> offline meetings (<u>16+</u> per month),<u>9</u> online meetings, including <u>6</u> international linkage activities to create a high-end brand.
- Co-organizes national conferences in the industry: WSIC,CFCVD2024&NICME,Alice, etc.



#### In-depth case studies newsletters & live surgery broadcast events :

- Published <u>41</u> cases (<u>7</u> cases / month); Covered ischemic \ hemorrhagic \ intracranial stenosis topics and products.
- Continue to promote the "Shenjie Guochao series of live surgery broadcast events.
- Theme-based activities were held for specific procedures: Feng Ming Lin Out, Story Exchange, Tong Da Zhi Yuan, BADDASS Webinar.
- Special events were held for young physicians:online forum for building stoke centers in primary hospitals.


### Neurovascular Launched Key Product – Kylin Flow Diverter





Kylin Flow Diverter Pipeline-PREMIER

Complete Occlusion Rate of Aneurysms at 12-month Post-procedure	88.15%	1	81.88%	2
Immediate Procedural Success Rate	100%		99.29%	
Incidence of New-onset Stroke in the Territory Supplied by the Treated Artery or Neurologic Death in 12 Months Post-procedure	0.70%		2.17%	
Incidence of Any Stroke in 12 months Post-procedure	2.11%		7.80%	
Incidence of Parent Artery Stenosis (>50%%)or Occlusion in 12 Months Post-procedure	2.21%		2.90%	
All-cause Mortality in 12 Months Post-procedure	0%		0.71%	



Participated in **10+** 

professional academic conferences, Conducted an international live surgery broadcast at Alice Neurointerventional Physician Forum

Complete Occlusion Rate of Aneurysms at 12-month Postprocedure 88.15%

Numbers of Provincial Procurement Platforms 21

#### Notes:

- 1. The 21st China Forum on Cerebrovascular Diseases (CFCVD) was held from April 26th to 28th, 2024. During the conference, Professor Liu Jianmin from Changhai Hospital in Shanghai made a significant announcement regarding the pre-market clinical data of the Kylin Flow Diverter.
- Pipeline Premier's data sources: Food and Drug Administration. PMAP100018/S015: FDA Summary of Safety and Effectiveness Data- Pipeline™ Flex Embolization Device. 2018. and Hanel RA, Kallmes DF, Lopes DK, et al. Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results. J Neurointerv Surg 2020; 12(1): 62-6.

#### China's first Flow Diverter with distal closure design

Peripheral-vascular Interventional Portfolio – Professional Academic Marketing Strategy






Peripheral-vascular Launched Key Product – Penguin Peripheral Venous Stent System







Active Participation in 14+ Professional Academic Conferences

The patency rate of target vessels reached 100% at 12 months postoperatively

Numbers of Provincial Procurement Platforms 26

Proximal beveled port, tapered taper and integrated

structure of the Peripheral Venous Stent System 为患者 恒创新/Innovation for quality life 16

Peripheral-vascular Launched Key Product – Unicorn Suture-mediated Closure System







According to the forecast, the annual number vascular closure procedures in China was about 0.28 million and it is expected to reach 3.78 million by 2030, with a CAGR of 26.9%.

Effectively **Simplify** and **accelerate** the process of vascular closure, improving the **Safety** and **Success** rate of procedures

Expanded suture range of 5F–22F, which is compatible with large bore sutures of 8F or above

The first self-developed suture-mediated closure system in China

Notes:1. Source: Frost & Sullivananalysis




#### Products Approved in Overseas Markets

	Product	Approved Region
Neur	Thrombite Clot Retriever Device	EU and 9 countries including U.K., Turkey, South Africa, Argentina, Russia, etc.
ovas cula	Aspiration Catheter	EU and 9 countries including U.K., Turkey, South Africa, Argentina, Russia, etc.
r	Microcatheter for Clot Retriever	EU and 7 countries including U.K., South Africa, Argentina, etc.
	Gekko Detachable Coil System	2 countries including Russia, Dominican Republic
	ZENFluxion Peripheral Drug Coated Balloon Catheter	EU and 10 countries including Turkey, Argentina, U.K., UAE, etc.
Deri	ZENFlow PTA Balloon Catheter	EU and 13 countries including Turkey, Argentina, U.K., UAE, etc.
Peri pher	ZENFlow PTA High Pressure Balloon Catheter	EU and 11 countries including Turkey, Argentina, U.K., UAE, etc.
al- vasc	ZENFlex Peripheral Stent System	EU and 13 countries including Argentina, U.K., UAE, etc.
ular	ZENFLEX Pro Peripheral Drug-Eluting Stent System	EU and 12 countries including Argentina, U.K., UAE, etc.
	ZENFlow Tiger PTA Balloon Catheter Large Diameter	3 countries including Brazil, Estonia, Latvia
	ZENFLOW Second Generation PTA Balloon Catheter	Brazil
	ZENFLOW HP PTA Second Generation High Pressure Balloon Catheter	Brazil

#### **Commercialized in 22 Countries/Regions**

#### Accelerate overseas layout, centering on Europe, further expanding into South America and Asia(mainly Russia and Korea)





#### Three-Year Results of Turkish Clinical Study of Thrombite thrombectomy device Released

- The study was a retrospective analysis of 525 patients who were included in the Turkish Interventional Neurology database and who had mechanical thrombectomy with the Thrombite device as the first choice between January 2020 and January 2023.
- $\succ$  The results of the study showed that **48.2%** (mTICI 2b/3)and

**33.9%** (mTICI 2c/3) were the first-pass recanalization rates. In the end, 82.1% of patients had effective recanalization (mTICI 2b/3).In the "first-pass" subgroup, the favorable functional result (modified Rankin Scale 0–2) was **51.8%**, while it was **41.6%** for the entire patient population.

- ➢ It is possible to utilize the Thrombite<sup>™</sup> thrombectomy device as the first-line option for LVO stroke thrombectomy, given the high rates of first-pass and final recanalization observed in the study.
- Since obtaining CE certification in 2020, the Thrombite thrombectomy device has been recognized and welcomed by local physicians for its innovative product design and high-quality product standards.

Three years' interventional neurology experience in Turkey with the Thrombite thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome

Çetin Kürşad Akpınar<sup>1</sup>, Erdem Gurkas<sup>2</sup>, Atilla Ozcan Ozdemir<sup>3</sup>, Hasan Doğan<sup>3</sup>\*, Ayşenur Önalan<sup>2</sup>, Serhan Yıldırım<sup>4</sup>, Zülfikar Memiş<sup>5</sup>, Emrah Aytaç<sup>6</sup>, Bilgehan Atılgan Acar<sup>7</sup>, Muhammed Nur Öğün<sup>8</sup>, Özlem Aykaç<sup>2</sup>, Zehra Uysal Kocabaş<sup>3</sup>, Türkan Acar<sup>7</sup>, Halil Alper Eryılmaz<sup>7</sup> and Berkhan Topaktaş<sup>9</sup>

Samsun Taihing and Research Hospital Stroke Center, Department of Neurology, Samsun University, Samsun, Tuihing -Narlal Dr. Lüft Indrey, "Eskischir Osmangad University, Hospital, Stroke Center, Department of Neurology, Health Sciences University, Islarbut, Tuihing, "Eskischir Osmangad University, Hospital, Stroke Center, Department of Neurology, Eskigehir Osmangad University, Eskischir, Türkiye, "Kocaell Cirki Hospital, Stroke Center, Kocaell, Turkiye, "Haseli Taining and Research Hospital, Stroke Center, Department of Neurology, Haurology, Eagang, Türkiye, "Staava University Hospital, Stroke Center, Department of Neurology, Balang, Türkiye, "Abant Izzet Baysal University Hospital, Stroke Center, Department of Neurology, Balan, Türkiye, "Abant Izzet Baysal University Hospital, Stroke Center, Department of Neurology, Balan, Türkiye,

TABLE 2 Details of endovascular treatment.

Procedural characteristics				
Onset to groin puncture (min)	215 (155-325)			
Groin puncture to successful recanalization (min)	29 (15-65)			
Balloon guide catheter, n (%)	26 (5)			
Combined aspiration-stent retriever technique, <i>n</i> (%)	479 (94.9)			
Reperfusion outcome, n (%)				
Successful first-pass recanalization (mTICI 2b/3), n (%)	243 (48.1)			
Excellent first-pass recanalization (mTICI 2c/3), n (%)	171 (33.9)			
Successful final recanalization (mTICI 2b/3), n (%)	443 (87.7)			
mTICI 3, n (%)	109 (21.6)			
mTICI 2c, n (%)	159 (31.5)			
mTICI 2b, n (%)	175 (34.7)			
Rescue treatment	39 (7.7)			

Values are mean (SD), median (IQR), or n (%) as appropriate. IQR, interquartile range; mTICI, modified treatment in cerebral infarction; SD, standard deviation.

Characteristics (n: EOE)	n (%)
Characteristics (n: 505)	
Age (mean ± SD)	68.6 ± 11.7
Gender (Male)	245 (48.5)
NIHSS score on admission, median (IQR)	13 (11-18)
CT ASPECT score, median (IQR)	7 (6–9)
Vascular risk factors, n (%)	
Hypertension	430 (85)
Diabetes mellitus	96 (19)
Atrial fibrillation	162 (32)
Coronary artery disease	56 (11)
Current smoking	126 (25)
Alcoholism	25 (5)
Hyperlipidemia	66 (13)
Stroke etiology, n (%)	
Cardioembolism	278 (55)
Large artery atherosclerotic disease	49 (9.8)
Carotid dissection	11 (2.2)
Unknown etiology	167 (33)
Intravenous rtPA, n (%)	195 (38.6)
Occlusion site, n (%)	
MCA M1 occlusion	213 (42.2)
MCA M2 occlusion	127 (25.1)
Tandem ICA-MCA occlusion	55 (10.9)
Carotid I, L, T occlusion	101 (20)
Anterior cerebral artery A1 occlusion	9 (1.8)

Values are mean (SD), median (IQR), or *n* (%) as appropriate. ASPECT, Alberta Stroke Program Early CT Score for MCA territory stroke; CT, computed tomography; IQR, interquarile range; NHSS, National Institutes of Health Stroke Scale.

Radiological and clinical outcomes	
Embolization to new territory, <i>n</i> (%)	11 (2.2)
Intracranial hemorrhage, n (%)	
Hemorrhagic infarction 1	39 (7.7)
Hemorrhagic infarction 2	61 (12.1)
Parenchymal hematoma 1	33 (6.5)
Parenchymal hematoma 2	23 (4.6)
Subarachnoid hemorrhage	9 (1.8)
Procedure-related dissection, <i>n</i> (%)	8 (1.5)
Vessel perforation	-
Outcome, <i>n</i> (%)	
Modified Rankin Scale 0-2	262 (41.6)
Modified Rankin Scale 3–6	243 (58.4)
All-cause mortality at 90 days	84 (16.6)


Values are mean (SD), median (IQR), or *n* (%) as appropriate. IQR, interquartile range; SD, standard deviation.

#### Notes:

1. Professor Erdem Gurkas from the University of Health Sciences in Turkey and Professor Çetin Kürşad Akpınar from Samsun Training and Research Hospital, along with other researchers, conducted a retrospective analysis on cases using Thrombite thrombectomy device from 2020 to 2023. The results were published in May 2024.

Leveraging a differentiated and comprehensive product portfolio, Embraced VBPs and increased products' market penetration







## R&D

 Advance R&D with great efficiency steadily and innovatively

## **Rich and Comprehensive Product Portfolio to Meet Huge Clinical Demand**



Intracranial Ischemic Stroke

Procedure Volume: 110,000 units (2023) BADDASS : Clot Retriever Device + Support Catheter + BGC Bolus removal and suction: Clot Retriever Device + Aspiration Catheter

> Intracranial Hemorrhagic Stroke Procedure Volume: 110,000 units (2023)

Coil + Flow Diverter + Intracranial Stent

#### Intracranial Stenosis

Procedure Volume: 65,000 units (2023)

Intracranial PTA balloon catheter (Rx) + Intracranial Drug Coated Balloon Catheter + Drug Coated Self-expandable Intracranial Stent

> Carotid Artery Stenosis Procedure Volume: 70,000 units (2023)


Carotid Rx PTA Balloon Catheter + Embolic Protection System + Carotid Stent

#### Intracranial Access

Procedure Volume: 355,000 units (2023)

Innovative Surgical Pathways : Radial Access Distal Support Catheter 、 Introducer Sheath

Other Access: Microcatheter for Coiling 、 Microcatheter for Intracranial Stent 、 Microcatheter for Clot Retriever 、 Neurovascular Guidewire et al.



#### Peripheral Artery Disease Procedure Volume: 170,000 units (2023) PTA Balloon (Normal 、High Pressure) + DCB + IVL +Cutting Ballon Peripheral Venous Disease VTE Prevention and Treatment (Filter placement, venous thrombus removal, etc.) Procedure Volume: 200,000 units (2023) Retrievable Inferior Vena Cava Filter + Snare Retrieval Kit for IVC Filter + Peripheral Thrombectomy System + Infusion Catheter Iliac vein compression syndrome (IVCS) Procedure Volume: 50.000~60.000 units (2023) Peripheral Venous Stent System Varicose Veins Procedure Volume: 80,000 units (2023) Endovenous Radiofrequency Ablation (RFA) Catheter+ Radiofrequency Generator Vascular Closure Procedure Volume: 约 350,000 units (2023) Suture-mediated Closure System + Vascular Closure System Others Hemodialysis Access : High Pressure Balloon Catheter Peripheral


Hemodialysis Access : High Pressure Balloon Catheter Peripheral Embolization Intervention : Peripheral Detachable Embolization Coils Aortic Intervention : Thoracic Aorta Stent Graft System



	23 Approved Products					6 Products			
	2020 2 Approved	2021-2022 9 Approved	2023 8 Approved	2024 4 Approved	2025 2 Approved	2026 3 Approved	2027 1 Approved		
Intracranial Ischemic Stroke	Thrombite Clot Retriever Device (CRD)	Balloon Guiding Catheter (BGC)	mp Aspiration Catheter Clot Retriever Device II						
Intracranial Stenosis		Second Generation Intracranial PTA balloon catheter (Rx)	Microcatheter for Intracranial Stent	Second Generation Intracranial PTA balloon catheter (Rx)	Intracranial Drug Coated Balloon Catheter	Drug Coated Intracranial Self-expandable Stent Intracranial Stent	Vertebral Artery DES		
Intracranial Hemorrhagic Stroke		Neurovascular Embolization Coil	ing Microcatheter for Flow Diverter	Mechanical Detachable Coil II	Embolization Assist Stent (Self-expandable Intracranial Stent)	t			
Intracranial Access	Intracranial Support Catheter	Distal Access Catheter Distal Access	Neurovasc ular Guidewire						
Carotid Artery Stenosis		Carotid Rx PTA Balloon Catheter		Embolic Protection System	为患者!	<b>Carotid Stent</b> 互创新/Innovation	for quality life		



#### **Embolization Assist Stent**



#### Indications

✓ Intracranial Hemorrhagic Stroke. It is often used in combination with a coil for the surgical treatment of complex intracranial aneurysms and wide-necked aneurysms.


#### Target Market

✓ Stroke epidemiology shows, there are 4 million new cases of stroke each year, of which hemorrhagic stroke accounts for about 20%, and wide-necked aneurysms clinically account for about 40% of the proportion of aneurysms.<sup>1</sup>

#### Product Characteristics

- ✓ Through-body visualization: Full-body radiopacity with nickel-titanium wrapped in platinum, making each filament visible under imaging. It has three radiopaque markers at both the proximal and distal ends, allowing surgeons to better assess the stent's deployment status.
- ✓ Stent's diverse filament count: Lightweight design, ease of opening and adherence ensure smooth deployment in various vessels. The super-elastic nickel-titanium material adapts well to tortuous vessels.
- Smooth push: The delivery system features release and retrieval radiopaque markers, ensuring the distal end of the microcatheter does not exceed the retrieval marker.
- Compatible with more indications: Its high metal coverage maintains collateral vessel circulation.

#### **Drug Coated Self-expandable Intracranial Stent**



Self-expandable Intracranial Stent

Rapamycin

- Indications
  - ✓ Intracranial Stenosis

#### Target Market

✓ According to the Frost & Sullivan Report, 30% to 50% of ischemic stroke cases are related to intracranial stenosis. The number of patients with intracranial stenosis in China amounted to 17.3 million in 2019, and is estimated to further increase to 27.9 million in 2030.

#### Product Characteristics


- ✓ Drug performance : Designed with appropriate drug loading capacity for thrombosis reduction, which can maintain the effective concentration of drug in the tissues appropriately, while reducing tissue cytotoxicity.
- Stent performance: Adopts a unique design of mesh and stent ribs, which ensures even stress and strain distribution, providing sufficient radial support for excellent wall apposition.
- ✓ Delivery system performance: Equipped with a multi-stage stiffness distribution, which is both supportive and flexible with a higher delivery ratio.

#### Note:

1. The literature "Preliminary Application of Neuroform Atlas Embolization Assist Stent for the Treatment wide-necked aneurysms," states that wide-necked aneurysms account for >40% of intracranial aneurysms.

## Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio – **34 Products**





Notes:1.Pantheris OCT-guided Peripheral-vascular Atherectomy Catheter Series, LightBox 3 OCT Imagining Consoles and Tigereye ST OCT-guided Peripheralvascular Chronic Total Occlusion-crossing Catheter are products of Avinger, a company in the United States, which are represented by our company.

恒创新/Innovation for quality life 刀思石

25



#### **Multi-spot Stent System**



#### Indications

✓ Balloon expanded femoral and popliteal artery dissection

#### Product Characteristics

- Refined design: Each stent is designed with a short-stent double-layer open-ring structure, with an anti-precession snap at one end and multiple visualization markers in the center.
- Optimized radial support design: Can be applied to a wide range of vessel sizes and different anatomical configurations. It causes less irritation to the vessel, reducing the possibility of intimal hyperplasia.
- ✓ Not commercialized products in China yet.

OCT-guided Peripheral-Vascular Targeted Atherectomy Catheter-Avinger Series



#### Indications

 Directional atherectomy, Lower extremity arterial stenosis

#### Product Characteristics

- The world's first and only directional atherectomy system with real-time imaging capabilities including OCT.
- Excellent vascular reducing effect and safety: Using three-dimensional visual guidance, allowing physicians to see real-time intravascular images. It facilitates easy operation, precise control of the cutting direction, and more efficient navigation to thoroughly remove plaque.
- The vascular reduction device can be used in conjunction with several of our products for the treatment to achieve synergistic effects.

#### **Balloon Expandable Covered Stent**



#### Indications

✓ Stenotic and/or occlusive lesions in the common iliac arteries and external iliac arteries

#### Product Characteristics

- Material and process: Cobalt chromium alloy tubing material for the main body of the stent;ePTFE coating with high expansion ratio and advanced process to ensure the long-term safety of stent implantation in the human body.
- Special design: Small delivery diameter, precise dilatation performance and special anti-falling design, with a variety of diameter sizes, which can be adapted to more complex lesions.
- Has been recommended as the preferred device for the treatment of lower extremity TASC C/D lesions by a number of domestic and international clinical guidelines.









# Optimize product portfolio and accelerate innovation based on clinical needs

- Optimize product portfolio by exploring clinical needs
- Continuously enhancing platform advantages and improving R&D efficiency
- Strengthen investment in innovative products and balance medium - and long-term development

# Continuously improve operational efficiency and profitability

- Relying on independent research and development technology platform, continuously accumulating professional manufacturing knowledge and consolidating proprietary advanced productivity.
- Actively embracing collective procurement to accelerate product entry and sales volume, and ultimately improve overall profitability.



#### Continued expansion of product market share based on solid commercialization capabilities

- Provide the market with differentiated technical features and a comprehensive product portfolio
- Gain market share through professional academic education and product strengths

# Further expansion into international markets

- Increased overseas registrations, including South America and Pan-Asia region
- Further expansion of the European team and strengthening of relationships with local doctors and distributors





Become China's Leading Minimally Invasive Medical Device Platform



+

0

Thank you

#### Please refer to 2024 Interim Results Announcement for further information Click to download the 2024 Interim Results Announcement



# **Financial Reports**

30

## **Consolidated Statements of Profit or Loss**

-100,745

Adjusted Net Profit / (Loss)



			Y	ember 31	Six months ended June 30					
RMB'000	2021 % (	of Revenue	<b>2022</b> % o	of Revenue	2023 % 0	f Revenue	2023 % of	f Revenue	2024 % or	f Revenue
Revenue	177,912	100%	334,090	100%	527,754	100%	230,131	100%	365,990	1009
Cost of sales	-46,031	-26%	-81,421	-24%	-142,766	-27%	-59,485	-26%	-105,077	-29%
Gross Profit	131,881	74%	252,669	76%	384,988	73%	170,646	74%	260,913	719
Selling and distribution expenses	-95,269	-54%	-140,137	-42%	-163,827	-31%	-74,939	-33%	-79,982	-229
Administrative expenses	-100,599	-57%	-109,337	-33%	-114,088	-22%	-50,358	-22%	-43,591	-129
Research and development expenses	-168,100	-94%	-233,461	-70%	-261,013	-49%	-130,806	-57%	-101,542	-28%
Other income	15,286	9%	12,165	4%	14,851	3%	5,198	2%	10,642	3%
Other expenses	-712	0%	-1,339	0%	-1,599	0%	-620	0%	-614	0%
Other gains/(losses) - net	5,058	3%	11,066	3%	-15,820	-3%	6,752	3%	-9,211	-39
Net impairment losses on financial assets	-21	0%	-24	0%	-15	0%	-6	-	-16	
Operating loss	-212,476	-119%	-208,398	-62%	-156,523	-30%	-74,133	-32%	36,599	10%
Finance income	13,094	7%	95,565	29%	79,040	15%	39,256	17%	34,579	9%
Finance costs	-307	0%	-722	0%	-1,251	0%	-346	0%	-1,215	0%
Finance income/(costs) – net	12,787	7%	94,843	28%	77,789	15%	38,910	17%	33,364	99
Share of net loss of an associate accounted for using the equity method	_		_		_		_		-1,098	179
Profit/(Loss) before income tax	-199,689	-112%	-113,555	-34%	-78,734	-15%	-35,223	-15%	68,865	199
Income tax expense	-	44.00/	-	2 40/		0%	-291	-	-	4.0
Profit/(Loss) for the year Profit/(Loss) attributable to	-199,689 -199,689	-112% -112%	-113,555 -113,555	-34% -34%	-78,734 -78,734	-15% -15%	-35, 514 -35, 514	<u> </u>	<u> </u>	19 <sup>.</sup> 19 <sup>.</sup>

7,033

-25,877

78,171 My/IIIIovation for qua 31 Ľ.J

-2%

-5,522

1%



	Year ende	Six months ended June 30		
RMB'000	2021	2022	2023	2024
Non-current assets				
Property, plant and equipment	178,270	290,243	538,540	615,262
Right-of-use assets	34,115	48,136	39,820	39,742
Intangible assets	4,889	9,637	9,686	34,721
Prepayments and other receivables	6,804	10,645	4,278	2,989
Financial assets at fair value through profit or loss	0	43,361	33,310	116,585
Term deposit	0	789,075	1,032,886	1,297,426
Total non-current liabilities	224,078	1,191,097	1,658,520	2,106,725
Current assets				
Inventories	57,272	119,244	166,542	169,388
Prepayments, other receivables and other current assets	37,616	81,025	38,588	38,523
Trade receivables	446	1,014	1,182	1,837
Financial assets at fair value through profit or loss	10,515	110,229	68,744	138,553
Term deposit	0	0	-	-
Cash and cash equivalents	1,500,000	545,140	355,546	498,861
Restricted cash	1,418,359	1,205,302	1,086,579	532,607
Total current assets	0	645	-	-
Total assets	3,024,208	2,062,599	1,717,181	1,379,769
RMB'000	3,248,286	3,253,696	3,375,701	3,486,494

为患者 恒创新/Innovation for quality life 32



Year ended December				Six months ended June 30
RMB'000	2021	2022	2023	2024
Non-current liabilities				
Deferred revenue	0	0	8,674	15,885
Lease liabilities	6,509	7,459	1,859	2,366
Total non-current liabilities	6,509	7,459	10,533	18,251
Current liabilities				
Trade and other payables	86,307	126,652	233,886	238,922
Current liabilities	3,420	9,601	19,922	26,382
Borrowings	0	0	50,000	75,000
Lease liabilities	2,896	6,543	4,018	3,875
Forward foreign exchange contract	0	278	0	0
Other current liabilities	4,480	9,010	9,957	14,426
Total current liabilities	97,103	152,084	317,783	358,605
Total liabilities	103,612	159,543	328,316	376,856
Equity attributable to equity holders of the Company				
Share capital	332,401	332,401	332,401	332,401
Share premium	2,270,033	2,270,033	2,270,033	2,265,109
Other reserves	841,007	928,685	1,014,452	999,770
Treasury shares	-9,149	-33,793	-87,594	-74,600
Accumulated losses	-289,618	-403,173	-481,907	-413,042
Total equity	3,144,674	3,094,153	3,047,385	3,109,638
Total equity and liabilities	3,248,286	3,253,696	3,375,701	3,486,494